ENTERA BIO LTD ENTX
SHS · Common Stock · CUSIP M40527109
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 23.7m as of 2020-12-31, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $3.81.
Trends to Q1 2021
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2019 | 4 |
| Q1 2020 | 4 |
| Q2 2020 | 6 |
| Q3 2020 | 6 |
| Q4 2020 | 6 |
| Q1 2021 | 9 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2020 | 1 | 1 |
| Q2 2020 | 2 | 2 |
| Q3 2020 | 2 | 3 |
| Q4 2020 | 2 | 3 |
| Q1 2021 | 7 | 2 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q2 2020 | $0 | $0 | — |
| Q3 2020 | $48.0k | $0 | 0.00 |
| Q4 2020 | $0 | $0 | — |
| Q1 2021 | $0 | $0 | — |
Biggest buyers
| Knoll Capital Management, LLC | Added | +50.0k |
| RENAISSANCE TECHNOLOGIES LLC | Added | +48.2k |
| MILLENNIUM MANAGEMENT LLC | New | +38.6k |
| Tower Research Capital LLC (TRC) | New | +22.0k |
| UBS Group AG | Added | +1.1k |
| Clearstead Advisors, LLC | New | +500 |
| Allworth Financial LP | New | +100 |
Biggest sellers
| Virtu Financial LLC | Sold out | -31.3k |
| Phoenix Financial Ltd. | Sold out | -12.4k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
BIOTECHNOLOGY VALUE FUND L P
13D · may seek influence
new · filed 2026-08-04
Stated purposeThe Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. April Securities Purchase Agreement and Registration Rights Agreement On April 1, 2026, … Full filing |
10.0% |
| OPKO HEALTH, INC. 13G · passive investor new · filed 2025-04-02 | 8.1% |
| TCG Crossover GP III, LLC 13G · passive investor new · filed 2026-08-04 | 7.1% |
| Vivo Opportunity Fund Holdings, L.P. 13G · passive investor new · filed 2026-08-04 | 6.9% |
Fell to 5% or below in the last year: Longitude Capital Partners V, LLC (4.6%, 2026-08-04), Seven Fleet Capital Management LP (4.1%, 2026-08-04)
Insider purchases and sales in Q1 2021
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q1 2021.
Holders, Q1 2021
| Manager | Shares | Change |
|---|---|---|
| Knoll Capital Management, LLC 4.45% of their portfolio | 1.8m $6.8m | Added +50.0k |
| RENAISSANCE TECHNOLOGIES LLC 0.00% of their portfolio | 120.4k $459.0k | Added +48.2k |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 38.6k $147.0k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 22.0k $84.0k | New |
| XTX Topco Ltd 0.02% of their portfolio | 11.6k $44.0k | First filing |
| UBS Group AG 0.00% of their portfolio | 1.6k $6.0k | Added +1.1k |
| Clearstead Advisors, LLC 0.00% of their portfolio | 500 $2.0k | New |
| Allworth Financial LP 0.00% of their portfolio | 100 $0 | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |